Fig 3. Importance table generated using lrna6 as outcome variable according to the increase of node purity induced by each predictive variable.

Method: random forest. (a) FPR < 10% (b) FPR ≤ 5% lrna0: log₁₀-transformed plasma HIV RNA at T0; lcd4_0: log₁₀-transformed CD4+ cell count at T0; x4_10: co-receptor HIV tropism as X4 (FPR < 10%); x4_5: co-receptor HIV tropism as X4 (FPR ≤ 5%); lrna6: log₁₀-transformed plasma HIV RNA after 6 months of cART; atv/r: atazanavir; drv/r: darunavir; tdfftc: tenofovir disoproxil fumarate/emtricitabine; abclam: abacavir/lamivudine; efv: efavirenz; dtg: dolutegravir; nvp: nevirapine; rpv: rilpivirine; ral: raltegravir; egv: elvitegravir.